Clinical

Dataset Information

0

Cetuximab in Treating Patients With Stage IV Colorectal Cancer

ABSTRACT: RATIONALE: Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of cetuximab in treating patients who have stage IV colorectal cancer that has not responded to previous treatment.

DISEASE(S): Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 2006482 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Json Xml

Similar Datasets

Clinical Cetuximab and Irinotecan in Treating Patients With Advanced Colorectal Cancer
| 2004178 | ecrin-mdr-crc
Clinical Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer
| 2006956 | ecrin-mdr-crc
Clinical Cetuximab Plus Combination Chemotherapy in Treating Patients With Stage IV Colorectal Cancer
| 2006481 | ecrin-mdr-crc
Clinical Neoadjuvant Cetuximab, Fluorouracil, and Pelvic Irradiation in Treating Patients With Locally Advanced or Locally Recurrent Rectal Cancer
| 2010935 | ecrin-mdr-crc
Clinical Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
| 2003507 | ecrin-mdr-crc
Clinical Monoclonal Antibody Therapy in Treating Patients With Colorectal Cancer
| 2004705 | ecrin-mdr-crc
Clinical Radiolabeled Monoclonal Antibody in Treating Patients With Advanced Colorectal Cancer
| 2002897 | ecrin-mdr-crc
Clinical Combination Chemotherapy Plus Cetuximab in Treating Patients With Liver Metastases From Colorectal Cancer
| 2008934 | ecrin-mdr-crc
Clinical Radiolabeled Monoclonal Antibody Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Recurrent Colorectal Cancer or Pancreatic Cancer
| 2003520 | ecrin-mdr-crc
Clinical Monoclonal Antibody F19 in Treating Patients With Advanced or Metastatic Cancer
| 2003478 | ecrin-mdr-crc